BioStratum Overview

  • Founded
  • 1994

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

BioStratum General Information


Developer of proprietary therapeutics designed to focus on scientific advances in basal lamina and related technologies. The company's proprietary therapeutics develop drug candidates that are directed against novel basal lamina extracellular targets involved in degenerative and invasive disease processes fundamental to diabetes, cancer and kidney disease, enabling patients to get help in wound repair and tissue regeneration.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 4825 Creekstone Drive
  • Durham, NC 27703
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioStratum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Out of Business 01-Aug-2016 000.00 Completed Out of Business
7. Later Stage VC 07-Nov-2011 00000 000.00 Completed Generating Revenue
6. Convertible Debt 14-Jan-2005 000 000.00 Completed Generating Revenue
5. Convertible Debt 22-Aug-2003 00.00 000.00 Completed Generating Revenue
4. Later Stage VC 29-Apr-2002 0000 0000 Completed Generating Revenue
3. Later Stage VC 27-Mar-2000 0000 0000 Completed Generating Revenue
2. Grant 01-Apr-1999 $16M $6M Completed Startup
1. Early Stage VC 01-Apr-1999 $6M $6M Completed Startup
To view BioStratum’s complete valuation and funding history, request access »

BioStratum Patents

BioStratum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-7381523-B2 Contacting pancreatic islet cells with somatostatin receptor binding agent; identifying promoters of insulin secretion Active 10-May-2004 0000000000
US-20070003986-A1 Contacting pancreatic islet cells with somatostatin receptor binding agent; identifying promoters of insulin secretion Active 10-May-2004 0000000000
US-20100305162-A1 Methods for the synthesis of pyridoxamine Active 09-Feb-2004 0000000000
US-8431712-B2 Methods for the synthesis of pyridoxamine Inactive 09-Feb-2004 0000000000 00
US-20050272781-A1 Protecting the hydroxyls of 3-hydroxy-4,5-dimethylol-2-picoline, reacting the 4-methylol group with an imide (especially potasssium phthalimide), cleaving the imide group to deprotect the amine group, and deprotecting the remaining hydroxy groups; post-amadori advanced glycation end-products. Active 09-Feb-2004 C07D213/66
To view BioStratum’s complete patent history, request access »

BioStratum Board Members (10)

Name Representing Role Since
Harry Penner Jr. Self Board Member 000 0000
Paul Marks Ph.D Self Board Member 000 0000
Per Samuelsson HealthCap Board Member 000 0000
Thomas D'Alonzo JD Self Board Member 000 0000
William Freytag Ph.D Self Chairman of the Board of Directors 000 0000
You’re viewing 5 of 10 board members. Get the full list »

BioStratum Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 07-Apr-2008 00000 0000 000.00 Biotechnology 00000 000
BioCrine 29-Apr-2002 Merger/Acquisition Drug Discovery
To view BioStratum’s complete investments and acquisitions history, request access »

BioStratum Subsidiaries (1)

Company Name Industry Location Founded
00000000 Drug Discovery Solna, Sweden
To view BioStratum’s complete subsidiaries history, request access »

BioStratum Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000000 07-Apr-2008 00000 00000 00 000.00 Completed
  • 4 buyers
To view BioStratum’s complete exits history, request access »